Sanofi successfully prices EUR 1 billion bond issue

PR Newswire/Les Echos/ 
PRESS RELEASE  
            Sanofi successfully prices EUR 1 billion bond issue  
Paris, France - August 29, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) 
announces that it has successfully priced its offering of EUR 1 billion of 
notes, due 2020, bearing interest at an annual rate of 1.875%.  
The issue is drawn under the Company's Euro Medium Term Note Programme.  
Sanofi intends to use the net proceeds of the offering for general corporate
purposes, including the repayment of existing borrowings.  
ING, Natixis, Société Générale and Unicredit acted as joint bookrunners for
the offering. RBS and Santander were co-lead managers for the offering.  
About Sanofi 
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY).  
DISCLAIMER  
This communication shall not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or
jurisdiction.  
The notes have not been and will not be registered under the Securities Act and
may not be offered or sold within the United States or to, or for the account 
or benefit of, U.S. persons except in certain transactions exempt from the
registration requirements of the Securities Act.  
This communication is only being distributed to and is only directed at (i)
persons who are outside the United Kingdom or (ii) investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (iii) high net worth
companies, and other persons to whom it may lawfully be communicated, falling
within Article 49(2)(a) to (d) of the Order or (iv) persons to whom an
invitation or inducement to engage in investment activity (within the meaning 
of section 21 of the FSMA) may otherwise lawfully be communicated or cause to 
be communicated (all such persons together being referred to as "relevant
persons"). The notes are only available to, and any invitation, offer or
agreement to subscribe, purchase or otherwise acquire such notes will be 
engaged in only with, relevant persons. Any person who is not a relevant person
should not act or rely on this document or any of its contents.  
No prospectus (including any amendment, supplement or replacement thereto) or
any other offering material has been prepared in connection with the offering 
of the notes that has been approved by the Autorité des marchés financiers or 
by the competent authority of another State that is a contracting to the 
Agreement on the European Economic Area and notified to the Autorité des 
marchés financiers; no notes have been offered or sold nor will be offered or 
sold, directly or indirectly, to the public in France; the prospectus or any 
other offering material relating to the notes have not been distributed or 
caused to be distributed and will not be distributed or caused to be 
distributed to the public in France; such offers, sales and distributions have 
been and shall only be made in France to persons licensed to provide the 
investment service of portfolio management for the account of third parties or 
to qualified investors (investisseurs qualifiés) other than individuals, in 
each case investing for their own account, all as defined in Articles L. 411-2,
D. 411-1 and D. 411-4, D. 734-1, D.744-1, D. 754-1 and D. 764-1 of the French 
Code monétaire et financier. The direct or indirect distribution to the public
in France of any so acquired notes may be made only as provided by Articles 
L. 411-1, L. 411-2, L. 412-1 and L. 621-8 to L. 621-8-3 of the French Code 
monétaire et financier and applicable regulations thereunder.  
Forward-Looking Statements 
Any statements made in this communication that are not statements of historical
fact, including statements about Sanofi's beliefs and expectations are
forward-looking statements and should be evaluated as such. Forward-looking
statements include statements that may relate to Sanofi's plans, objectives,
strategies, goals, future events, future revenues or performance, and other
information that is not historical information. Sanofi does not undertake, and
specifically disclaims, any obligation or responsibility to update or amend any
of the information above except as otherwise required by law.  
Additional Information: 
This communication is neither an offer to purchase nor a solicitation of any
offer to sell any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
jurisdiction.  
Contacts:  
Media Relations               Investor Relations 
Laurence Bollack              Sébastien Martel 
Tel.: + (33) 1 53 77 46 46    Tel.: + (33) 1 53 77 45 45 
mr@sanofi.com                 ir@sanofi.com 
                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Aug/29/2013 07:14 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.